The effect of the PPAR-γ agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model

Oncology Research

Volumn 18, Issue 8, 2010, Pages 387-393

  Krieger Hinck, Nina ^a   Schumacher, Udo ^a   Müller, Alexander ^a   Valentiner, Ursula ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Neuroblastoma; PPAR agonists; Rosiglitazone; SCID mouse

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 77950555454     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12644422320708     Document Type: Article

References (37)

1. Maris, J. M.; Hogarty, M. D.; Bagatell, R.; Cohn, S. L. Neuroblastoma. Lancet 369:2106-2120; 2007.
2. Morgenstern, B. Z.; Krivoshik, A. P.; Anderson, P. M. Wilms' tumour and neuroblastoma. Acta Paediatr. Suppl. 445:78-85; 2004.
3. Simon, T. Neuroblastom. Der Urologe 44:543-555; 2005.
4. Brodeur, G. M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 3:203-216; 2003.
5. Sato, Y.; Sasaki, H.; Kobayashi, Y.; Haruki, N.; Toyama, T.; Kondo, S.; Fujii, Y. Expression of PPAR-gamma is correlated with the clinical course of neuroblastoma. J. Pediatr. Surg. 38:205-210; 2003.
6. Ponthan, F.; Johnson, J. I.; Klevenvall, L.; Castro, J.; Kogner, P. The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo. Int. J. Cancer 104:418-424; 2003.
7. Kim, E. J.; Park, K. S.; Chung, S. Y.; Sheen, Y. Y.; Moon, D. C.; Song, Y. S.; Kim, K. S.; Song, S.; Yun, Y. P.; Lee, M. K.; Oh, K. W.; Yoon, D. Y.; Hong, J. T. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: Association with extracellular signal-regulated kinase signal pathway. J. Pharmacol. Exp. Ther. 307:505-517; 2003.
8. Panigrahy, D.; Shen, L. Q.; Kieran, M. W.; Kaipainen, A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Investig. Drugs 12:1925-1937; 2003.
9. Auwerx, J. PPAR-γ, the ultimate thrifty gene. Diabetologia 42:1033-1049; 1999.
10. Yang, Y. C.; Tsao, Y. P.; Ho, T. C.; Choung, I. P. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int. J. Gynecol. Cancer 17:418-425; 2007.
11. Allred, C. D.; Kilgore, M. W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell. Endocrinol. 235:21-29; 2005.
12. Koeffler, H. P. Peroxisome proliferator-activated receptor gamma and cancers. Clin. Cancer Res. 9:1-9; 2003.
13. Katoh, M.; Feldhaus, S.; Schnitzer, T.; Bauer, S.; Schumacher, U. Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate. Cancer Lett. 8:7-15; 2004.
14. Freudlsperger, C.; Moll, I.; Schumacher, U.; Thies, A. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17:325-332; 2006.
15. Elstner, E.; Müller, C.; Koshizuka, K.; Williamson, E. A.; Park, D.; Asou, H.; Shintaku, P.; Said, J. W.; Heber, D.; Koeffler, H. P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95: 8806-8811; 1998.
16. Mueller, E.; Sarraf, P.; Tontonoz, P.; Evans, R. M.; Martin, K. J.; Zhang, M.; Fletcher, C. Terminal differentiation of human breast cancer through PPAR-gamma. Mol. Cell 1: 465-470; 1998.
17. Sarraf, P.; Mueller, E.; Jones, D.; King, F. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat. Med. 4:1046-1052; 1998.
18. Valentiner, U.; Carlsson, M.; Erttmann, R.; Hildebrandt, H.; Schumacher, U. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213: 157-168; 2005.
19. Han, S. W.; Greene, M. E.; Pitts, J.; Wada, R. K.; Sidell, N. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin. Cancer Res. 7:98-104; 2001.
20. Servidei, T.; Morosetti, R.; Ferlini, C.; Cusano, G.; Scam-bia, G.; Mastrangelo, R.; Koeffler, H. P. The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol. Res. 14:345-354; 2004.
21. Kerr, J. F. R.; Wyllie, A. H.; Currie, A. R. Apoptosis: A basic biological phenomenom with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-257; 1972.
22. Hall, P. A. Assessing apoptosis: A critical survey. Endocr. Relat. Cancer 6:3-8; 1999.
23. Sharma, R.; Adam, E.; Schumacher, U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: Mitosis, apoptosis and cell differentiation. Br. J. Cancer 76:1011-1016; 1997.
24. Jojovic, M.; Schumacher, U. Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett. 152:151-156; 1999.
25. Han, S.; Wada, R. K.; Sidell, N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 61: 3998-4002; 2001. (Pubitemid 32720962)
26. Servidei, T.; Morosetti, R.; Ferlini, C.; Cusano, G.; Scam-bia, G.; Mastrangelo, R.; Koeffler, H. P. The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines. Oncol. Res. 14:345-354; 2004.
27. Cellai, I.; Benvenuti, S.; Luciani, P.; Galli, A.; Ceni, E.; Simi, L.; Baglioni, S.; Muratori, M.; Ottanelli, B.; Serio, M.; Thiele, C. J.; Peri, A. Antineoplastic effects of rosiglita-zone and PPARgamma transactivation in neuroblastoma cells. Br. J. Cancer 95:879-888; 2006.
28. Shimada, T.; Kojima, K.; Yoshiura, K.; Hiraishi, H.; Terano, A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50:658-664; 2002.
29. Lin, M. S.; Chen, W. C.; Bai, X.; Wang, Y. D. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J. Dig. Dis. 8:82-88; 2007.
30. Tsubouchi, Y.; Sano, H.; Kawahito, Y.; Mukai, S.; Yamada, R.; Kohno, M.; Inoue, K.; Hla, T.; Kondo, M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 270:400-405; 2000.
31. Kim, K. Y.; Ahn, J. H.; Cheon, H. G. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species forma-liferativetherapyinvivowithpositronemissiontomogration. Mol. Pharmacol. 72:674-685; 2007.
32. Keshamouni, V. G.; Reddy, R. C.; Arenberg, D. A.; Joel, B.; Thannickal, V. J.; Kalemkerian, G. P.; Standiford, T. J. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 8:100-108; 2004.
33. Mueller, E.; Smith, M.; Sarraf, P.; Kroll, T.; Aiyer, A.; Kaufman, D. S.; Oh, W.; Demetri, G.; Figg, W. D.; Zhou, X. P.; Eng, C.; Spiegelman, B. M.; Kantoff, P. W. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc. Natl. Acad. Sci. USA 97:10990-10995; 2000.
34. Kubota, T.; Koshsuza, K.; Williamson, E. A. Ligand for peroxisome proliferator-activated receptory (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:3344-3352; 1998.
35. Demetri, G. D.; Fletcher, C. D. M.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B. M.; Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Nat. Acad. Sci. USA 96:3951-3956; 1999.
36. Yee, L. D.; Williams, N.; Wen, P.; Young, D. C.; Lester, J.; Johnson, M. V.; Farrar, W. B.; Walker, M. J.; Povoski, S. P.; Suster, S.; Eng, C. Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res. 1:246-252; 2007.
37. Barthel, H.; Cleij, M. C.; Collingridge, D. R.; Hutchinson, O. C.; Osman, S.; He, Q.; Luthra, S. K.; Brady, F.; Price, P. M.; Aboagye, E. O. 3'-deoxy-3'-(18F)fluorothymidine as a new marker for monitoring tumor response to antipro-liferative therapy in vivo with positron emission tomography. Cancer Res. 63:3791-3798; 2003.